Signs Agreement to Acquire K.F. (Cambodia) Ltd. to Further Strengthen DSA Supply Chain; Transaction Expected to be Accretive to Non-GAAP Earnin...
− Full Year 2025 Preliminary* Net Product Revenues of $2,987 Million (81% Growth vs. 2024), Driven Primarily by Preliminary* Total TTR Revenues o...
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-met...
Building on strong momentum in 2025, new product launches and regulatory milestones planned for 2026 to support goal of at least $2 billion in combined...
Etienna Bio, Inc., a biotechnology company focused on next-generation autologous and cell-enabled biomaterials for regenerative and aesthetic application...
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondans...
Clinical data from pivotal trial in patients undergoing lumpectomy confirm strong safety profile and growing performance benefits Primary safety endp...
Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-...
— Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease — HUTCHMED (China) Lim...
Akkermansia muciniphila postbiotic receives both U.S. FDA dietary supplement clearance and Korean functional ingredient approval with muscle health ...
Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, announced an agree...
First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases...
Rebrand announced in June as part of Fujifilm Life Sciences Group restructuring becomes official FUJIFILM Irvine Scientific becomes FUJIFILM Biosciences...
- Hoth Therapeutics (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies for underserved medical needs, ...
© 2026 Biopharma Boardroom. All Rights Reserved.
